Share the news WhatsApp Facebook X LinkedIn Two-part Phase 1b trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of inhaled pan-JAK inhibitor KN-002 Study is being conducted at [ … ]